Background: Weight loss is frequently observed in pancreatic cancer patients. We aimed to study the prognostic impacts of weight loss early during chemotherapy. Methods: A total of 72 patients of Chinese ethnicity with unresectable pancreatic cancer who underwent chemotherapy were reviewed. Critical weight loss (CWL) was defined as weight loss ≥ 5% within one month after treatment. The prognostic impact of weight loss and CWL were analyzed. Results: 47 patients (65.3%) had weight loss after one month of treatment, with 14 (19.4%) suffering from CWL. Baseline characteristics were similar between patients with and without CWL. The median OS and Time-to-treatment-failure (TTF) of patients with CWL were shorter than those without CWL (OS: 4.8 months [CWL] versus [vs.] OS 7.1 months [No CWL]; TTF 1.6 months [CWL] vs. 3.2 months [No CWL]; both P < 0.01). CWL was an independent adverse prognosticator for OS (Hazard Ratio [HR] = 2.50; P = 0.01) and TTF (HR = 2.71; P < 0.01). Other independent prognosticators for OS were serum albumin <35 mg/dl and CA19-9 ≥ 1000 IU/ml, while CWL was the only independent prognosticator for TTF (HR 2.71 [95% CI 1.33–5.52]; P < 0.01). Conclusions: Development of CWL in early course of chemotherapy was associated with worse prognosis in Chinese patients with unresectable pancreatic cancers.
The optimal radiotherapy regimen following mastectomy and immediate breast reconstruction remains under active investigation. In particular, the safety of moderate hypofractionation (HF) compared to conventional fractionation (CF) for postmastectomy radiotherapy (PMRT) has not been clearly established. Given the growing adoption of HF in breast cancer treatment, a thorough synthesis comparing complication outcomes is essential to guide clinical practice. A comprehensive search was conducted in Embase, MEDLINE, and Cochrane CENTRAL up to January 10, 2025. Studies comparing HF (2.4-2.7 Gy/fraction) and CF (1.8-2.0 Gy/fraction) in patients undergoing immediate breast reconstruction with PMRT were included. Studies involving partial breast irradiation or accelerated fractionation were excluded. Risk of bias was assessed using RoB 2 and ROBINS-I V2; certainty of evidence was evaluated using GRADE. A random-effects meta-analysis was performed, estimating pooled odds ratios (ORs) with 95 % confidence intervals (CIs). The protocol was registered in PROSPERO (CRD42023471267). Eleven studies (n = 3611), including three randomized controlled trials, were included. HF and CF demonstrated similar risks of major complications (OR: 0.83; 95 % CI: 0.51-1.35; p = 0.45; n = 5). No significant differences were observed for infection, wound dehiscence, or hematoma among photon-based studies. HF was associated with a lower risk of capsular contracture (OR: 0.38; 95 % CI: 0.15-0.99; p = 0.05; n = 5). Only one study evaluated quality of life, reporting no difference in physical well-being. HF offers a safety profile comparable to CF following breast reconstruction and may be preferred due to its reduced treatment burden and a potentially lower risk of capsular contracture.
1 June 2024 in Asia-Pacific Journal of Oncology Nursing
This review aimed to summarize the benefits, side effects, physics measurements, and patient- and clinician-reported outcomes of Mepitel film (MF) in preventing radiation dermatitis (RD) for cancer patients. The online database PubMed was searched from inception to April 15, 2024 with the search terms “Mepitel film” or “Mepitel.” Articles of any study design evaluating MF for the prevention of RD were included. Non-human studies were excluded. The database search identified 119 articles and 13 of them were included in this review. Across these studies, MF was found to be beneficial in reducing RD and improved patient- and clinician-reported outcomes in breast and head and neck cancers. Side effects of MF included itchiness, acne, allergic reaction, tightness, discomfort, and poor film adherence, but patient dropouts were uncommon. MF did not cause a bolus effect or increased skin dose in physics measurements. MF is a safe and effective intervention for preventing acute RD. It should be recommended in breast cancer patients where the data is more robust. Further research is needed to evaluate MF's efficacy on patients with different skin tones, its cost-effectiveness, and identifying patients who most benefit from MF relative to other effective interventions.
16 July 2025 in Breast Cancer Research and Treatment